Inhibikase Posts Wider Loss in Q2

Inhibikase Therapeutics (IKT) reported a wider-than-expected GAAP net loss of $0.11 per share for Q2 2025, missing analyst estimates, with total net loss nearly doubling to $9.9 million compared to Q2 2024. This was primarily driven by significant increases in R&D and SG&A expenses, up 70.7% and 195.0% respectively, due to recent acquisition charges, pipeline investments, and one-time severance costs. Despite remaining pre-revenue, the company ended the quarter with $87.7 million in cash and equivalents, down from year-end 2024, as it focuses on advancing its lead candidate, IKT-001 for PAH, towards a Phase 2b trial targeted for H2 2025, without providing specific financial guidance for upcoming quarters.

Analysis

Inhibikase Therapeutics (IKT) reported a challenging second quarter for 2025, characterized by widening losses and escalating operational expenses, despite making progress on its lead clinical candidate. The company's GAAP net loss per share of $0.11 missed analyst estimates of a $0.08 loss, and more importantly, the absolute GAAP net loss nearly doubled to $9.9 million from $5.0 million in the prior-year period. This was driven by a substantial surge in operating costs, with SG&A expenses rising 195.7% and R&D expenses increasing significantly, fueled by the CorHepta acquisition, including a $7.4 million write-off of in-process R&D, and one-time severance payments. The reported per-share loss improvement from $0.66 in Q2 2024 is misleading, as it stems entirely from a massive increase in the average share count to 90.0 million from 7.5 million, indicating significant shareholder dilution. While the company maintains a cash position of $87.7 million, its cash burn has accelerated, with a decline of nearly $10 million since year-end 2024. Operationally, the sole focus was on advancing IKT-001 for PAH into a Phase 2b trial in H2 2025, but the lack of updates on its Parkinson's or oncology programs and the absence of any forward-looking financial guidance create considerable uncertainty regarding future cash runway and pipeline diversification.

Key Decisions for Investors

• Investors should scrutinize the company's accelerating cash burn rate against its $87.7 million cash position, as the lack of financial guidance suggests a potential need for further dilutive financing before any data readouts.
• The investment case for IKT is now heavily concentrated on the successful execution and outcome of the IKT-001 Phase 2b trial; progress on trial initiation and enrollment in H2 2025 is the primary near-term catalyst to monitor.
• Disregard the headline year-over-year EPS improvement, as it masks a doubling of the absolute net loss and significant shareholder dilution, which are more accurate reflections of the company's financial health.
• The absence of updates on the Parkinson's (IkT-148009) and oncology pipelines represents a key risk, and investors should weigh the concentration risk of a single late-stage asset against the company's valuation.